Combined anti-trypanosomal and anti-inflammatory nanotherapy for the treatment of Chagas disease

Project: Research project

Description

Dr. Evan Scott has expertise in the fabrication and in vivo application of targeted nanomaterials for the controlled delivery of therapeutics. He will be responsible for the design, synthesis, characterization and drug loading of polymeric nanocarriers containing benznidazole payloads. He will oversee the scalable fabrication and shipping of these materials for experiments in mouse models of trypanosoma parasitemia and autoimmune myocarditis at Cedars-Sinai, which will be performed by Dr. Engman.
StatusActive
Effective start/end date3/6/192/28/21

Funding

  • Cedars-Sinai Medical Center (0001552826//1R21AI44529-01)
  • National Institute of Allergy and Infectious Diseases (0001552826//1R21AI44529-01)

Fingerprint

Trypanosoma
Parasitemia
Chagas Disease
Nanostructures
Myocarditis
Anti-Inflammatory Agents
Pharmaceutical Preparations
Therapeutics
benzonidazole